標的型タンパク質分解のためのE3リガゼKEAP1の活用
Jieli Wei1, Fanye Meng1, Kwang-Su Park1
1Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Journal of the American Chemical Society
|September 14, 2021
まとめ
この研究では,標的型タンパク質分解のためにKEAP1 E3リガスを用いた新しいタンパク質分解標的化キメラ (PROTAC) が導入されています. 新しいPROTAC,MS83は,BRD4とBRD3のタンパク質を効果的に分解し,耐久性と抗増殖活性性を高めます.
科学分野:
- 生物化学
- 分子生物学
- 薬物の発見
背景:
- タンパク質分解標的キメラ (PROTAC) は新興の治療戦略である.
- PROTACは,標的型タンパク質分解のために,ユビキチン- プロテアソームシステム (UPS) を利用する.
- 現在,PROTACの開発では限られたE3リガスが利用されています.
研究 の 目的:
- PROTAC媒介によるタンパク質分解におけるKEAP1 E3リガスの可能性を調査する.
- KEAP1を用いたBRD4/3/2をターゲットとする新しいPROTAC (MS83) の開発と特徴付け.
- 既存のPROTACと比較してMS83の有効性,耐久性,および抗増殖活性を評価する.
主な方法:
- KEAP1リガンドをBRD4/3/2結合剤に結合することによって,PROTAC (MS83) の設計と合成.
- 濃度,時間,KEAP1およびUPS依存性を含むタンパク質分解を評価するための細胞ベースの測定法.
- MS83とCRBNリクルートするPROTAC (dBET1) の分解運動と反増殖効果の比較
- アイソフォーム特異的なBRD4の分解分析
主要な成果:
- MS83はKEAP1とUPSに依存した方法でBRD4とBRD3のタンパク質レベルを効果的に低下させた.
- MS83は,MDA- MB-468細胞におけるDBET1と比較して,BRD4/3のより持続的な分解を示した.
- MDA- MB-231細胞では,BRD4の短い同位体と長い同位体の選択的な分解が観察されました.
- MS83は,dBET1と比較して優れた抗増殖活性を示した.
結論:
- KEAP1 E3リガゼは,標的型タンパク質の分解にうまく利用できます.
- MS83は強力で選択的なPROTACであり,既存の薬よりも性能が向上しています.
- この研究は,PROTACの開発のためのE3リガースのレパートリーを拡張し,新しい治療の可能性を提供します.
関連する概念動画
Regulated Protein Degradation
7.9K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.9K
The Proteasome
1.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.2K
Export of Misfolded Proteins out of the ER
4.3K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
4.3K
The Unfolded Protein Response
5.4K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.4K
Regulation of the Unfolded Protein Response
2.7K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.7K
Receptor Downregulation in MVBs
2.3K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.3K


